MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00592-026-02730-4

Медицинская библиотека · Acta diabetologica · 2026

Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.

Arora Sakshi, Amna Fnu, Akbarpoor Fatemeh, Rajdeep Dhvanit, Khalid Muhammad, Machado Gabriel Moura, Maalin Niman, Rehman Asad Ur, Abreu Marconi

СтатьяОбзорПеревод пока не подготовлен

Аннотация

AIMS: We meta-analyzed randomized trials to assess efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) after bariatric surgery.

METHODS

We searched PubMed, Embase, and Cochrane Central for randomized trials comparing GLP-1 RAs with placebo after bariatric surgery. Primary outcomes were change in body weight (kg) and HbA1c (%) at 6 and 12 months. We also assessed percent total body weight loss (%TBWL), quality of life, and adverse events. We pooled mean differences (MDs) with 95% confidence intervals (CIs) using random effects and assessed heterogeneity with I² statistic. We also performed an exploratory subgroup analysis that compared very early (≤ 2 months) versus late (≥ 18 months) initiation after surgery.

RESULTS

Seven RCTs (n = 460) met inclusion criteria; all evaluated liraglutide. GLP-1 RAs increased weight loss at 6 months (MD - 5.33 kg; 95% CI - 9.42 to - 1.23; p = 0.02) but not at 12 months (MD - 5.05 kg; 95% CI - 22.14 to 12.05; p = 0.33). GLP-1 RAs increased %TBWL at 6 months (MD 5.13%; 95% CI 2.14 to 8.11; p = 0.007) but not at 12 months (MD 3.96%; 95% CI - 3.33 to 11.26; p = 0.18). HbA1c did not differ at 6 or 12 months. Quality of life improved at 6 months in the trials reporting this outcome. Gastrointestinal adverse events were similar between groups. Subgroup analyses suggested differences by initiation timing.

CONCLUSION

GLP-1 RA therapy improved short-term weight outcomes after bariatric surgery, with no statistically significant between-group differences at 12 months. Timing of initiation may influence response and should be explored in trials with longer follow up.

TRIAL REGISTRY: PROSPERO ID CRD420251251321.

Для цитирования: Arora Sakshi, Amna Fnu, Akbarpoor Fatemeh, Rajdeep Dhvanit, Khalid Muhammad, Machado Gabriel Moura, Maalin Niman, Rehman Asad Ur, Abreu Marconi. Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.. Acta diabetologica. 2026. DOI: 10.1007/s00592-026-02730-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.